An observational study in Osteoporosis, Osteoarthritis, Hip and Hip Fractures, sponsored by Imelda Hospital, Bonheiden. Recruiting at 1 site in Belgium. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Imelda Hospital, Bonheiden · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.
Among the 32 studies in Osteoporosis with a site in Belgium, this one is one of 2 that started in 2022, is one of 5 observational ones, and was the 30th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:
AgNovos Healthcare, LLC · Sites in Belgium
Women only
AgNovos Healthcare, LLC · Sites in Belgium, Austria, Canada and 8 more countries
Ages 65–91 · Women only
AgNovos Healthcare, LLC · Sites in Belgium
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 160 across 456 observational studies indexed under Osteoporosis.
Median enrollment 218 across the 27 interventional studies, 54 across the 5 observational. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Imelda Hospital, Bonheiden has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoporosis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07594639AgNovos Healthcare, LLCGRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP) | 2027-04-01 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Osteoporosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.
Patients undergoing hip arthroplasty for hip osteoarthritis or osteoporotic hip fractures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Blood and bone marrow cell collection
Other: Blood and bone marrow cell collection
Collection of blood and bone marrow
Gene Set Enrichment Analysis (GSEA) Normalized Enrichment Score (NES)
Time frame: One day
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Dec 2028, 82 months after the start.
Of 115 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 82 months is above that.
Counting every sponsor, half of 126 studies reached it within 51 months; a quarter within 24 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imelda Hospital, Bonheiden